Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 488Lymphoma, T-Cell, Cutaneous 92Carcinoma, Non-Small-Cell Lung 89Mycosis Fungoides 72Neoplasm Metastasis 71Skin Neoplasms 62Neoplasms 61Sezary Syndrome 60Carcinoma, Renal Cell 60Lymphoma, Non-Hodgkin 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma 53Breast Neoplasms 52Leukemia, Lymphocytic, Chronic, B-Cell 50Lymphoma, Follicular 47Lymphoma, Mantle-Cell 46Lymphoma, B-Cell, Marginal Zone 46Squamous Cell Carcinoma of Head and Neck 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Hodgkin Disease 44Colorectal Neoplasms 43Burkitt Lymphoma 43Lymphoma, Large-Cell, Immunoblastic 41Ovarian Neoplasms 38Multiple Myeloma 35Uveal Melanoma 34Leukemia, Hairy Cell 33Lymphoma, Large-Cell, Anaplastic 32Sarcoma 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Xeroderma Pigmentosum × Dermatologic × Clear all
NCT04155190 2023-05-31

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Sol-Gel Technologies, Ltd.

Phase 2 Terminated
47 enrolled
Dermatologic

Rombo syndrome, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Syndrome, Xeroderma Pigmentosum

Data powered by HemOnc (CC BY 4.0) Colophon âš¡